AT101 exerts a synergetic efficacy in gastric cancer patients with 5-FU based treatment through promoting apoptosis and autophagy

• Published in: Oncotarget Vol. 7; no. 23; pp. 34430 - 34441
• Main Authors: Wei, Xi, Duan, Wei, Li, Ying, Zhang, Sheng, Xin, Xiaojie, Sun, Lei, Gao, Ming, Li, Qing, Wang, Dong
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 07.06.2016
• Subjects: AC133 Antigen - antagonists & inhibitors; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents - pharmacology; Apoptosis - drug effects; Autophagy - drug effects; Cell Line, Tumor; Cell Movement - drug effects; DNA-(Apurinic or Apyrimidinic Site) Lyase - antagonists & inhibitors; Drug Synergism; Female; Fluorouracil - pharmacology; Gossypol - analogs & derivatives; Gossypol - pharmacology; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubule-Associated Proteins - antagonists & inhibitors; Middle Aged; Nanog Homeobox Protein - antagonists & inhibitors; Receptor, ErbB-2 - metabolism; Research Paper; Stomach Neoplasms - drug therapy; Xenograft Model Antitumor Assays; gastric cancer; APE1; AT101; Her-2 positive; 5-FU

Gastric cancer remains a disease with a high mortality rate despite of multiple therapeutic strategies. So far, it is very important to develop new treatment approaches to improve current therapeutic efficacy in gastric cancer. Apurinic/apyrimidinic endonuclease (APE1) involves in DNA base excision...